Tokyo Tape
Sign in
← Noile-Immune Biotech

Quarterly report · Q3

4893.TEDINET S100S9G1
Period2023-01-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedNo
Data checks8 of 8 passed
Key figures · 21
MetricValuePeriodScopeSource row
Operating income−¥496m2023-01-01 → 2023-09-30StandaloneOperating income
Ordinary income−¥849m2023-01-01 → 2023-09-30StandaloneOrdinary income
Ordinary income−¥384m2022-01-01 → 2022-12-31StandaloneOrdinary income loss (5-year summary)
Profit before tax−¥849m2023-01-01 → 2023-09-30StandaloneIncome before income taxes
Net income−¥850m2023-01-01 → 2023-09-30StandaloneProfit loss
Net income−¥387m2022-01-01 → 2022-12-31StandaloneNet income loss (5-year summary)
Total assets¥6.2bnat 2023-09-30StandaloneAssets
Total assets¥4.6bnat 2022-12-31StandaloneAssets
Total liabilities¥202mat 2023-09-30StandaloneLiabilities
Total liabilities¥340mat 2022-12-31StandaloneLiabilities
Net assets / equity¥6.0bnat 2023-09-30StandaloneNet assets
Net assets / equity¥4.3bnat 2022-12-31StandaloneNet assets
Cash and deposits¥5.7bnat 2023-09-30StandaloneCash and deposits
Cash and deposits¥4.5bnat 2022-12-31StandaloneCash and deposits
EPS (basic)¥-20.812023-01-01 → 2023-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-0.392023-07-01 → 2023-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-9.872022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
Equity ratio96.6%at 2023-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio92.5%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Shares issued43,276,765at 2023-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued39,579,865at 2022-12-31StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 204
ItemContextValueUnit
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember6901000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember6901000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember4300617000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember5967033000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember4641032000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember6168786000JPY
Operating revenues rev oaCurrentYTDDuration_NonConsolidatedMember314144000JPY
Operating costs1 cos exp oaCurrentYTDDuration_NonConsolidatedMember2093000JPY
Research and development costs cos exp oaCurrentYTDDuration_NonConsolidatedMember496014000JPY
General and administrative expenses cos exp oaCurrentYTDDuration_NonConsolidatedMember311894000JPY
Operating costs and expenses cos exp oaCurrentYTDDuration_NonConsolidatedMember810001000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-495857000JPY
Interest income noiCurrentYTDDuration_NonConsolidatedMember44000JPY
Other noiCurrentYTDDuration_NonConsolidatedMember0JPY
Non operating incomeCurrentYTDDuration_NonConsolidatedMember44000JPY
Foreign exchange losses noeCurrentYTDDuration_NonConsolidatedMember545000JPY
Listing expenses noeCurrentYTDDuration_NonConsolidatedMember343444000JPY
Stock issuance cost noeCurrentYTDDuration_NonConsolidatedMember8808000JPY
Non operating expensesCurrentYTDDuration_NonConsolidatedMember352798000JPY
Ordinary incomeCurrentYTDDuration_NonConsolidatedMember-848611000JPY
Income before income taxesCurrentYTDDuration_NonConsolidatedMember-848611000JPY
Income taxes currentCurrentYTDDuration_NonConsolidatedMember1821000JPY
Income taxesCurrentYTDDuration_NonConsolidatedMember1821000JPY
Profit lossCurrentYTDDuration_NonConsolidatedMember-850433000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-11-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第９期第３四半期（自2023年７月１日　至2023年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)ノイルイミューン・バイオテック株式会社
Company name in english cover pageFilingDateInstantNoile-Immune Biotech Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　玉田　耕治
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区芝大門二丁目12番10号
Telephone number address of registered headquarter cover pageFilingDateInstant03-5843-7819
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役管理部長　永井　寛子
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区芝大門二丁目12番10号
Telephone number nearest place of contact cover pageFilingDateInstant03-5843-7819
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役管理部長　永井　寛子
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE38453
Fund codeFilingDateInstant－
Security codeFilingDateInstant48930
Filer name in japaneseFilingDateInstant
Original text (Japanese)ノイルイミューン・バイオテック株式会社
Filer name in englishFilingDateInstantNoile-Immune Biotech Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 8 of 8 passed
balance sheet identitynon_consolidated 2022-12-31pass rounding
balance sheet identitynon_consolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-09-30pass